{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:19:50Z","timestamp":1787663990299,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82274367"],"award-info":[{"award-number":["No. 82274367"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nucleos(t)ide analogue (NA) discontinuation in chronic hepatitis B (CHB) can produce two clinically divergent trajectories: a minority of patients achieve sustained hepatitis B surface antigen (HBsAg) loss or off-treatment viral control, whereas others develop hepatitis flares without virological benefit. Recent longitudinal studies have begun to define the host immune correlates of these outcomes. This Mini Review separates direct evidence from NA-withdrawal cohorts from mechanistic evidence obtained in other CHB settings. Direct human data suggest that beneficial outcomes are associated with recovery of HBsAg-specific memory B-cell activity, plasmablast expansion, stronger T follicular helper collaboration, and preserved hepatitis B virus (HBV)-specific T-cell function. In contrast, high inhibitory-receptor expression on global T cells, persistent inflammatory chemokine signatures, and greater post-flare alanine aminotransferase variability are associated with non-beneficial flares. immune complexes formed by HBsAg and antibodies to HBsAg provide an additional humoral readout that may reflect both flare risk and the quality of HBsAg decline. These observations are promising but remain exploratory: cohorts are small, flare definitions are heterogeneous, assays are not standardized, and most signatures lack external validation. Immune markers should therefore be viewed as candidate correlates to be integrated with viral biomarkers, liver-disease severity, and close post-withdrawal monitoring rather than as stand-alone criteria for stopping therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1949176","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:31:42Z","timestamp":1787661102000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune correlates of outcomes after nucleos(t)ide analogue withdrawal in chronic hepatitis B: direct evidence, mechanistic context, and candidate biomarkers"],"prefix":"10.3389","volume":"17","author":[{"given":"Zihao","family":"Xu","sequence":"first","affiliation":[{"name":"School of Chinese Medicine, Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Chinese Medicine, Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangbin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine Affiliated to Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Hubei University of Chinese Medicine","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","author":"Razavi-Shearer","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD IDSA Practice Guideline on treatment of chronic hepatitis B","volume":"83","author":"Ghany","year":"2026","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-026-11108-1","article-title":"APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update","author":"You","year":"2026","journal-title":"Hepatol Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323979","article-title":"Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis","volume":"71","author":"Hall","year":"2022","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.015","article-title":"Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study)","volume":"82","author":"Dongelmans","year":"2025","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Garc\u00eda-L\u00f3pez","year":"2021","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"Van B\u00f6mmel","year":"2023","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002759","article-title":"Limited sustained remission after nucleos(t)ide analog withdrawal: results from a large, global, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study)","volume":"119","author":"Hirode","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16920","article-title":"Hepatitis B surface antigen seroclearance rate after stopping nucleos(t)ide analogues in chronic hepatitis B\u2014A systematic review and meta\u2010Analysis","volume":"40","author":"Maung","year":"2025","journal-title":"J Gastro Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002176","article-title":"Withdrawal of long-term nucleotide analog therapy in chronic hepatitis B: outcomes from the withdrawal phase of the HBRN immune active treatment trial","volume":"118","author":"Feld","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core\u2010related and surface antigens at end of nucleos(t)ide analogue treatment to predict off\u2010therapy relapse risk","volume":"49","author":"Hsu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100720","article-title":"Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies","volume":"5","author":"Zeng","year":"2023","journal-title":"JHEP Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16029","article-title":"High end\u2010of\u2010treatment hepatitis B core\u2010related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy","volume":"44","author":"Hume","year":"2024","journal-title":"Liver Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0188","DOI":"10.1097\/HC9.0000000000000188","article-title":"Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants","volume":"7","author":"Thompson","year":"2023","journal-title":"Hepatol Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020493","article-title":"Emerging diagnostic tools to decide when to discontinue nucleos(t)ide analogues in chronic hepatitis B","volume":"9","author":"Papatheodoridi","year":"2020","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00649-z","article-title":"A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook","volume":"19","author":"Kramvis","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333309","article-title":"Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal","volume":"75","author":"Lens","year":"2026","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf569","article-title":"Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analog withdrawal in HBeAg-negative chronic hepatitis B","volume":"233","author":"Hume","year":"2026","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324646","article-title":"Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection","volume":"71","author":"Aliabadi","year":"2022","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16850","article-title":"Model to predict on\u2010treatment restoration of functional HBV \u2010specific CD8+ cell response foresees off\u2010treatment HBV control in eAg \u2010negative chronic hepatitis B","volume":"55","author":"Pe\u00f1a\u2010Asensio","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0694","DOI":"10.1097\/HC9.0000000000000694","article-title":"HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B","volume":"9","author":"Traum","year":"2025","journal-title":"Hepatol Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101875","article-title":"Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B","volume":"8","author":"Holmberg","year":"2026","journal-title":"JHEP Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"22590","DOI":"10.1038\/s41598-023-50216-y","article-title":"Treatment cessation in HBeAg-negative chronic hepatitis B: clinical response is associated with increase in specific proinflammatory cytokines","volume":"13","author":"Holmberg","year":"2023","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16968","article-title":"Stopping nucleot(s)ide analogues in non\u2010cirrhotic HBeAg \u2010negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels","volume":"56","author":"Hall","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S360202","article-title":"Soluble programmed cell death-1 is a novel predictor of HBsAg loss in chronic hepatitis B patients when long-term nucleos(t)ide analog treatment is discontinued","volume":"15","author":"Liao","year":"2022","journal-title":"IDR"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13804","article-title":"Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof\u2010of\u2010concept study","volume":"52","author":"Chang","year":"2022","journal-title":"Hepatol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1016\/j.cell.2024.05.038","article-title":"Therapeutic potential of co-signaling receptor modulation in hepatitis B","volume":"187","author":"Andreata","year":"2024","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01928-4","article-title":"Attenuated effector T cells are linked to control of chronic HBV infection","volume":"25","author":"Heim","year":"2024","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07630-7","article-title":"A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection","volume":"631","author":"Bosch","year":"2024","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611976","article-title":"Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection","volume":"16","author":"Shu","year":"2025","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0625","DOI":"10.1097\/HC9.0000000000000625","article-title":"HBV and HBsAg strongly reshape the phenotype, function, and metabolism of DCs according to patients\u2019 clinical stage","volume":"9","author":"Dumolard","year":"2025","journal-title":"Hepatol Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15226","article-title":"Myeloid\u2010derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy","volume":"49","author":"Pal","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1427519","article-title":"Peripheral NK cell phenotypic alteration and dysfunctional state post hepatitis B subviral particles stimulation in CHB patients: evading immune surveillance","volume":"15","author":"Selim","year":"2024","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1657367","article-title":"Alterations in peripheral blood NK cell subsets and function in patients with HBeAg-positive chronic hepatitis B during pregnancy","volume":"15","author":"Shen","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.03.038","article-title":"The core cellular network modulates immune phenotype switching in hepatitis B","volume":"70","author":"Chen","year":"2025","journal-title":"Sci Bull"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1506526","article-title":"The role of immune regulation in HBV infection and hepatocellular carcinogenesis","volume":"16","author":"Zheng","year":"2025","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-026-11058-8","article-title":"A combined model of HBcrAg, anti-HBc, and anti-HBs predicts recurrence after functional cure of chronic hepatitis B","volume":"20","author":"Lin","year":"2026","journal-title":"Hepatol Int"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70465","article-title":"Clinical trial: hepatitis B virus genotype and a combination of end\u2010of\u2010Treatment biomarkers predict severe flares after nucleos(t)ide analogue cessation","volume":"63","author":"Furquim d\u2019Almeida","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1421712","article-title":"AAV-HBV mouse model replicates the intrahepatic immune landscape of chronic HBV patients at single-cell level","volume":"16","author":"Concei\u00e7\u00e3o-Neto","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546915","article-title":"Cure of chronic hepatitis C virus infection after DAA treatment only partially restores the functional capacity of exhausted T cell subsets: a systematic review","volume":"16","author":"Apol","year":"2025","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1831739","article-title":"PD-1\/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B","volume":"17","author":"Li","year":"2026","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.07.019","article-title":"PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial","volume":"82","author":"Li","year":"2025","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002125","article-title":"Randomized trial of tenofovir with or without peginterferon alfa followed by protocolized treatment withdrawal in adults with chronic hepatitis B","volume":"118","author":"Terrault","year":"2023","journal-title":"Am J Gastroenterol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1949176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:31:43Z","timestamp":1787661103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1949176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1949176"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1949176","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1949176"}}